CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

• Published in: Clinical cancer research 2005-07, Vol.11 (14), p.5281-5291
• Main Authors: Lopes de Menezes, Daniel E, Peng, Jing, Garrett, Evelyn N, Louie, Sharianne G, Lee, Sang H, Wiesmann, Marion, Tang, Yan, Shephard, Lee, Goldbeck, Cheryl, Oei, Yoko, Ye, Helen, Aukerman, Sharon L, Heise, Carla
• Format: Article
• Language: English
• Subjects: Acute Myelogenous Leukemia (AML); Animals; Antineoplastic agents; Benzimidazoles - pharmacology; Biological and medical sciences; Cell Proliferation; CHIR-258; Disease Models, Animal; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; FLT3; fms-Like Tyrosine Kinase 3; Hematologic and hematopoietic diseases; Humans; Immunohistochemistry; kinase inhibitor; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - pathology; Leukemia, Myeloid, Acute - veterinary; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Mice; Mice, SCID; Neoplasm Transplantation; Pharmacology. Drug treatments; Proto-Oncogene Proteins - antagonists & inhibitors; Proto-Oncogene Proteins - genetics; Quinolones - pharmacology; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor Protein-Tyrosine Kinases - genetics; Tandem Repeat Sequences; Transplantation, Heterologous; Tumor Cells, Cultured
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-05-0358

Purpose: Fms-like tyrosine kinase 3 (FLT3) encodes a receptor tyrosine kinase (RTK) for which activating mutations have been identified in a proportion of acute myelogenous leukemia (AML) patients and associated with poor clinical prognosis. Given the relevance of FLT3 mutations in AML, we investigated the activity of CHIR-258, an orally active, multitargeted small molecule, with potent activity against FLT3 kinase and class III, IV, and V RTKs involved in endothelial and tumor cell proliferation in AML models. Experimental Design: CHIR-258 was tested on two human leukemic cell lines in vitro and in vivo with differing FLT3 mutational status [MV4;11 cells express FLT3 internal tandem duplications (ITD) versus RS4;11 cells with wild-type (WT) FLT3]. Results: Antiproliferative activity of CHIR-258 against MV4;11 was ∼24-fold greater compared with RS4;11, indicating more potent inhibition against cells with constitutively activated FLT3 ITD. Dose-dependent down modulation of receptor phosphorylation and downstream signaling [signal transducer and activator of transcription 5 (STAT5) and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase] in MV4;11 cells with CHIR-258 confirmed the molecular mechanism of action. Target modulation of phospho-FLT3, phospho-STAT5, and phospho-ERK in MV4;11 tumors was achieved at biologically active doses of CHIR-258. Tumor regressions and eradication of AML cells from the bone marrow were shown in s.c. and bone marrow engraftment leukemic xenograft models. Tumor responses were characterized by decreased cellular proliferation and positive immunohistochemical staining for active caspase-3 and cleaved poly(ADP-ribose) polymerase, suggesting cell death was mediated in part via apoptosis. Conclusions: Our data indicate that CHIR-258 may be an effective therapy in FLT3-associated AML and warrants clinical trials.